AR042258A1 - Aza peptidos - Google Patents
Aza peptidosInfo
- Publication number
- AR042258A1 AR042258A1 ARP030104425A ARP030104425A AR042258A1 AR 042258 A1 AR042258 A1 AR 042258A1 AR P030104425 A ARP030104425 A AR P030104425A AR P030104425 A ARP030104425 A AR P030104425A AR 042258 A1 AR042258 A1 AR 042258A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- aza
- peptides
- dementia
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000003625 skull Anatomy 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Péptidos que comprenden al menos un aza-amino ácido y que tienen la capacidad de romper las hojas beta, que pueden ser usados para el tratamiento y prevención de enfermedades como por ejemplo el mal de Alzheimer, demencia pugilística (incluyendo traumatismo de cráneo), hemorragia cerebral hereditaria con amiloidosis del tipo holandés (HCHWA-D) y demencia vascular con angiopatía amiloide. Reivindicación 1: Un compuesto de la fórmula (1) general donde R1 es seleccionado de H, C2-6 acilo y C1-6 alquilo; R2, R3, R4 y R5 son seleccionados independientemente de H y C1-6 alquilo; R6 es seleccionado de -OH, y NR7R8, donde R7 y R8 son seleccionados independientemente de H y C1-6 alquilo; X1, X2, X3, X4, y X5 son seleccionados independientemente de CR9 o N donde R9 es seleccionado de H y C1-6 alquilo y con la condición de que al menos uno de X1, X2, X3, X4 y X5 es N, así como también cualquier derivado quiral del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02102673 | 2002-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042258A1 true AR042258A1 (es) | 2005-06-15 |
Family
ID=32405771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104425A AR042258A1 (es) | 2002-12-02 | 2003-12-01 | Aza peptidos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060281686A1 (es) |
| EP (1) | EP1567546A2 (es) |
| JP (1) | JP2006520321A (es) |
| AR (1) | AR042258A1 (es) |
| AU (1) | AU2003298260A1 (es) |
| CA (1) | CA2505150A1 (es) |
| NO (1) | NO20053237D0 (es) |
| WO (1) | WO2004050689A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472563B (en) * | 2009-04-28 | 2013-02-27 | Univ Leicester | Method of preparing hairpin and cyclic polyamides |
| EP3966223A4 (en) * | 2019-05-09 | 2023-08-02 | The Feinstein Institutes for Medical Research | PEPTIDOMIMETICS, SYNTHESIS AND USES THEREOF |
| US11883461B2 (en) | 2019-05-09 | 2024-01-30 | The Feinstein Institutes For Medical Research | HMGB1 antagonist treatment of severe sepsis |
| CN113924290A (zh) | 2019-05-09 | 2022-01-11 | 范因斯坦医学研究院 | 硫代半肼基甲酸酯及其用途 |
| CN114126619B (zh) | 2019-05-09 | 2024-03-15 | 范因斯坦医学研究院 | 用于合成肽模拟物的化合物 |
| WO2020227603A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1081809B (it) * | 1977-06-07 | 1985-05-21 | Isf Spa | Idrazono cefalosporine |
| US5948763A (en) * | 1995-06-07 | 1999-09-07 | New York University | Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits |
| KR20020079731A (ko) * | 1999-11-05 | 2002-10-19 | 액소닉스, 인코포레이티드. | 아밀로이드, 아밀로이드-유사 침착물, 또는 β-쉬이트가풍부한 그의 병리학적 전구체로의 비정상적 단백질 폴딩과관련된 질환의 치료에 있어서 생체내에서 사용하기에적합한 펩티드 동족체 및 유사체 |
-
2003
- 2003-12-01 US US10/537,246 patent/US20060281686A1/en not_active Abandoned
- 2003-12-01 WO PCT/EP2003/015033 patent/WO2004050689A2/en not_active Ceased
- 2003-12-01 AR ARP030104425A patent/AR042258A1/es not_active Application Discontinuation
- 2003-12-01 JP JP2004556312A patent/JP2006520321A/ja active Pending
- 2003-12-01 EP EP03795985A patent/EP1567546A2/en not_active Withdrawn
- 2003-12-01 AU AU2003298260A patent/AU2003298260A1/en not_active Abandoned
- 2003-12-01 CA CA002505150A patent/CA2505150A1/en not_active Abandoned
-
2005
- 2005-07-01 NO NO20053237A patent/NO20053237D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006520321A (ja) | 2006-09-07 |
| NO20053237L (no) | 2005-07-01 |
| WO2004050689A2 (en) | 2004-06-17 |
| EP1567546A2 (en) | 2005-08-31 |
| AU2003298260A1 (en) | 2004-06-23 |
| CA2505150A1 (en) | 2004-06-17 |
| NO20053237D0 (no) | 2005-07-01 |
| US20060281686A1 (en) | 2006-12-14 |
| WO2004050689A3 (en) | 2004-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120683A1 (es) | Compuestos de benzoti(di)azepina y su uso como ácido biliar | |
| BRPI0811280B8 (pt) | compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos | |
| AR120679A1 (es) | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar | |
| PE20191615A1 (es) | Compuestos quimicos como inhibidores de la actividad de la interleuquina-1 | |
| ECSP066879A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| UY30287A1 (es) | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias | |
| ECSP066858A (es) | Inhibidores de gsk-3 | |
| ECSP066358A (es) | PIPERAZINA CON GRUPO FENIL OR-SUSTITUIDO Y SU USO COMO INHIBIDORES GlyT1 | |
| GT200300219A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| DOP2005000004A (es) | "derivados sulfonamida para el tratamiento de enfermedades" | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
| AR043875A1 (es) | Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| UY28450A1 (es) | Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos. | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| ECSP056164A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| AR042258A1 (es) | Aza peptidos | |
| AR037612A1 (es) | Compuestos derivados de 4-piperidinilamina, su empleo, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| AR056862A1 (es) | 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion | |
| NO20081845L (no) | Imidazolforbindelser for behandling av neurologiske lidelser | |
| CR8636A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| EA200601607A1 (ru) | Сульфонамидные соединения для лечения нейродегенеративных расстройств | |
| AR036130A1 (es) | Compuesto sustituido de gama-lactona, procedimiento para prepararlo, medicamento y uso de dicho compuesto para preparar un medicamento | |
| BRPI0509559A (pt) | compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos | |
| AR001998A1 (es) | Derivados de 6-metoxi-1h-benzotriazol-5-carboxamida, las composiciones farmaceuticas que los contienen y procedimientos para su preparacion | |
| AR038260A1 (es) | Compuestos derivados de benzotiazina y de benzotiazidina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |